Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs TDENV LAV (Primary)
- Indications Dengue
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.